VITALII
VODOL
AZSKYI-
STOCK.ADOBE.COM
Bio/Pharma Outsourcing Innovation February 2025 BioPharm International
®
|
Pharmaceutical Technology
®
25
T
h e m a r k e t r e s e a r c h a n d c o n s u l t i n g f i r m
DelveInsight predicts that a global contract de-
velopment and manufacturing organization
(CDMO) market already valued at more than
$100 billion could potentially grow by almost half
that amount, to an eventual total value of nearly $144
billion, over the second half of the 2020s (1).
T hat expa nsion across t he ma rket, wh ich rep-
resents a theoretical compound annual growth rate
of 6.5%, not only ref lects the rise in some serious
diseases, various cancers among them, but also the
increasing popularity of outsourcing in the drug de-
velopment process—which, DelveInsight said, comes
with certain benefits in cost savings (1).
The firm was even retained by an unnamed "large
pharma client" looking to improve its API and finished
dosage development to produce a one-off report with
the objective of benchmarking top CDMO candidates
for outsourcing its projects, analyzing the CDMOs' R&D,
manufacturing, and commercialization capabilities (2).
Such attention to and emphasis on this research un-
derlines the importance the bio/pharma industry is
currently investing in its outsourcing decisions, and
as the CDMO market continues to grow, the details of
those decisions figure to get more and more precise.
Key outsourcing trends
To that end, when CPHI shared its top outsourcing
trends for CDMOs across the globe for 2024, several
key themes emerged. Chief among these were more
careful consideration of geographic diversification
and its implications, end-to-end or "one-stop-shop"
organizations being able to improve efficiency and
sca labi lit y, market sh if ts increasingly driven by
merger and acquisition (M&A) activity, and equal re-
sponsibility between the drugmaker and the CDMO/
Savings and Sustainability
Sought by Pharma Partners
Patrick Lavery
With 2025 now in full swing, industry is already observing significant
developments in outsourcing services, new facilities, and M&A activity thus far this year.
